Brokers Offer Predictions for Oncobiologics FY2026 Earnings

Oncobiologics, Inc. (NASDAQ:OTLK) – Research analysts at Ascendiant Capital Markets boosted their FY2026 earnings per share estimates for Oncobiologics in a research note issued to investors on Thursday, September 10th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings per share of ($0.45) for the year, up from their previous estimate of ($0.51). Ascendiant Capital Markets has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Oncobiologics’ current full-year earnings is ($0.47) per share. Ascendiant Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.08) EPS, Q1 2027 earnings at ($0.08) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Oncobiologics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings raised shares of Oncobiologics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 12th. BTIG Research reiterated a “buy” rating and set a $4.00 price objective on shares of Oncobiologics in a research note on Friday, August 14th. Finally, HC Wainwright increased their price objective on shares of Oncobiologics to $1.60 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $5.20.

Oncobiologics Stock Up 0.6%

Shares of Oncobiologics stock opened at $0.68 on Thursday. The business’s fifty day moving average is $0.95 and its two-hundred day moving average is $0.74. Oncobiologics has a fifty-two week low of $0.16 and a fifty-two week high of $2.54. The firm has a market cap of $164.79 million, a PE ratio of -0.88 and a beta of 0.74.

Oncobiologics (NASDAQ:OTLK) last announced its earnings results on Friday, August 14th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.97 million.

Insider Activity at Oncobiologics

In other news, Director Ghiath M. Sukhtian acquired 2,525,252 shares of the stock in a transaction on Wednesday, August 12th. The stock was bought at an average price of $0.99 per share, with a total value of $2,499,999.48. Following the completion of the transaction, the director directly owned 24,617,320 shares of the company’s stock, valued at $24,371,146.80. The trade was a 11.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Faisal Ghiath Sukhtian acquired 95,398 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were purchased at an average price of $1.05 per share, for a total transaction of $100,167.90. Following the purchase, the director directly owned 220,972 shares of the company’s stock, valued at approximately $232,020.60. This trade represents a 75.97% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.80% of the company’s stock.

Institutional Investors Weigh In On Oncobiologics

A hedge fund recently bought a new position in Oncobiologics stock. NewEdge Advisors LLC bought a new stake in shares of Oncobiologics, Inc. (NASDAQ:OTLK) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 16,722 shares of the company’s stock, valued at approximately $27,000. 11.20% of the stock is owned by institutional investors and hedge funds.

Oncobiologics Company Profile

Oncobiologics, Inc, now known as Outlook Therapeutics, Inc (NASDAQ: OTLK), is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines. The company specializes in biologic therapies intended to address diseases affecting the eye, with an emphasis on retinal disorders.

The company’s lead product is ONS-5010, an ophthalmic formulation of bevacizumab developed for intravitreal treatment of wet age-related macular degeneration and other retinal conditions.